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REPLY
As a follow-up to our study on the effects of aggressive versus
conventional lipid-lowering therapy by simvastatin in human
atherosclerotic lesions (1), Dr. Spence stated that “Corti et al.
found no difference in vessel wall area measured by magnetic
resonance imaging (MRI)” and that “investigators wishing to
measure effects of antiatherosclerotic therapy would be well served
by measuring carotid plaque volume using three-dimensional
ultrasound” on the importance of the methodology and location of
atherosclerotic lesions when measuring the effect of antiarterio-
sclerotic therapies. Our study (1) was the second publication from
a randomized, double-blind trial involving 51 newly diagnosed,
clinically asymptomatic hyperlipidemic patients. Changes in ath-
erosclerotic lesions were assessed by using high-resolution nonin-
vasive MRI. The major conclusion of our study is the importance
of lowering plasma low-density lipoprotein (LDL) cholesterol
levels rather that the statin dose. As such, we reported that the
observed changes in aortic plaque parameters were related to the
reduction in LDL-cholesterol levels rather than to the doses of
statin. The study design and early observations were published in
2001 (2).
Dr. Spence is partially correct in his statement that we found no
differences in plaque volume in the study. We did observe a
correlation with LDL-lowering and aortic lesion changes. Dr.
Spence is correct in that we did not achieve statistically significant
changes in the carotid lesions, although the percentages of volume
change were identical in both the aorta and carotids. These
observations strongly support the role of the severity/thickness of
the lesions at baseline as a major determinant for detecting the
effectiveness of the therapeutic interventions. In this regard, using
an MRI-based imaging modality and the same treatments but in a
population with more advanced disease (clinically documented
coronary artery disease), Lima et al. (3) reached a conclusion similar
to ours. In their study, the changes were significant after only six
months of treatment (3). The importance of lesion severity for
detecting treatment-induced changes in plaque volume is clearly
emphasized by these two studies. Furthermore, these findings have
been corroborated by studies performed more recently.
The major advantages of using MRI for plaque assessment are
the noninvasive approach and the high sensitivity and specificity of
this modality that permits a small sample size of subjects. This
observation has been confirmed by a recent study with five sites
that has reported sample size calculation for clinical trials using
MRI for quantitative assessment of carotid atherosclerosis (4).
We do agree with Dr. Spence that MRI is not the only imaging
modality capable of detecting changes in plaque lesions. The
objective of our study was not to conclude that MRI is the only
imaging modality to be used for such purpose. We want to
emphasize that the important fact in inducing lesion regression is
an effective and maintained lipid-lowering intervention. If the
intervention is effective, MRI and any of the other imaging
modalities should clearly validate the beneficial effects.
*Juan Jose Badimon, PhD, FACC, FAHA
Roberto Corti, MD
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Aspirin Resistance and
Atherothrombotic Disease
We read with interest the comprehensive review of “aspirin resistance”
by Mason et al. (1). We suggest, based on our recent experience, that
two less well-explored mechanisms may contribute to what is clearly
a composite of several processes.
Interindividual pharmocodynamic variability occurs with most
drugs. Aspirin is no different; thus aspirin resistance assays may
reflect pharmacodynamic heterogeneity. Mason et al. (1) identify
genotypic variation in cyclooxygenase (COX)-1 as a potential but
unproven pharmacodynamic mechanism. We recently explored
this hypothesis in a population with stable coronary artery disease
(CAD) and determined that COX-1 haplotype modulates platelet
response to aspirin determined by two established laboratory assays
of COX inhibition: arachidonic acid-induced platelet aggregation
and thromboxane B2 generation in serum. Much of the effect,
however, was associated with a single COX-1 haplotype carried by
12% of the population, and thus, although contributing to the
problem, this does not explain the higher rates of aspirin resistance
reported in several studies (2).
Mason et al. (1) also discuss pharmacokinetic resistance to
aspirin and specifically the role of drug interaction and dose
response; however, variability in aspirin formulation is another
possible factor. It is worth recalling that initial dose-finding studies
were performed with plain aspirin, which is rapidly absorbed from
the stomach and inhibits platelet cyclooxygenase in the presystemic
circulation. As mentioned by Mason et al. (1) dosing with 100 mg
is sufficient to completely inhibit platelet cyclooxygenase. Accord-
ingly, current American College of Cardiology/American Heart
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Association guidelines give aspirin a class I indication for use in
patients with chronic stable angina (level of evidence A) (3). This
recommendation, however, has been interpreted to embrace a
myriad of aspirin formulations: various salts, polymer-coated in
rapid-release (compressed, soluble), buffered, and enteric-coated
preparations, which may influence the bioavailability of the prep-
aration (4). We recently evaluated the effect of low-dose enteric-
coated aspirin preparations on platelet COX-1 in both healthy
volunteers and patients with stable CAD. Low-dose enteric-coated
aspirin failed to inhibit platelet cyclooxygenase in some individuals.
Specifically younger, heavier patients and those with a history of
prior myocardial infarction were less likely to have an adequate
response (5).
Not withstanding the initial uncontrolled studies, we agree that
the jury is still out on the clinical relevance of aspirin resistance.
However, it is not an unreasonable goal that a drug has its intended
pharmacological effect. In the case of aspirin, near complete
inhibition of platelet cyclooxygenase is most likely to be achieved
with the correct preparation and dose.
*Andrew O. Maree, MSc, MD
Hani Jneid, MD
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REPLY
We appreciate the comments and criticisms voiced by Dr. Maree
and colleagues. With respect to pharmacodynamic heterogeneity
and genotypic variation in cyclooxygenase (COX)-1, we applaud
the investigators’ work and agree that the single haplotype iden-
tified may contribute to, but not entirely explain, the phenomenon
of “aspirin resistance.” As suggested in our study (1), variation in
aspirin responsiveness is most likely explained by a combination of
several processes. If true, however, that 12% of the investigators’
cohort with stable coronary artery disease carried the specific
COX-1 haplotype, it may prove interesting to study this popula-
tion in greater detail. We also find interesting the observation by
Dr. Maree et al. that low-dose (75 mg) enteric-coated aspirin
failed to inhibit platelet COX in certain individuals. Although
previously studied in some detail, the effects of aspirin dose and
formulation are still worthy of further investigation. Finally, we
agree that the biological validity and clinical relevance of “aspirin
resistance” remains somewhat unproven.
*Peter J. Mason, MD, MPH
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The Emperor’s New
Clothes Are Loose: Lower Body
Mass Index, Not Calorie Restriction,
Accounts for Improved Diastolic Function
A recent study in JACC (1) concludes that diastolic function is
improved in individuals on long-term calorie restriction (CR)
compared to those eating a “Western diet.” We would like to point
out that other studies demonstrate a correlation between diastolic
dysfunction and body mass index (BMI) as an independent factor.
In the study by Fontana et al. (1), control subjects eating a Western
diet had an average BMI of 27 kg/m2; the CR adherents had a
BMI of 19.7 kg/m2. Mortality and morbidity rise significantly
above a BMI of 22 kg/m2, and a BMI of 25 kg/m2 is (generously)
considered by U.S. Department of Agriculture panelists as the
upper limit of normal weight. Therefore, a BMI of 27 kg/m2 is
well within the category of overweight. An average male height 5
ft 9 inches with a BMI of 20 kg/m2 weighs 135 lbs. If his BMI is
27 kg/m2, he weighs 35% more at 182 lbs, a 47-lb difference!
In a study of the effect of isolated obesity on diastolic function
Pascual et al. (2), state: “Subclinical left ventricular diastolic
dysfunction is present in all grades of isolated obesity, correlates
with BMI, and is associated with increased systolic function in the
early stages of obesity.” In that study, a BMI between 25 and 29.9
kg/m2 was classed as “slight obesity.” Another study (3) states:
“Diastolic function was negatively correlated with age, BMI,
systolic blood pressure, diastolic blood pressure and left ventricular
mass index.”
In addition, control subjects had 26% body fat, and the CR
subjects had 9.3%. Obesity is known to raise tumor necrosis
factor-alpha and other pro-inflammatory cytokines (4). Long-term
inflammatory effects may change ventricular elasticity, but the
observed difference may be due more to the large difference in body
fat and BMI than to the CR versus Western diets. It is probable
that the difference in diastolic function attributed to CR is at least
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